F00-F99 F30-F39 F40-F48
Conditions
Interventions
Group 1: PROVIDE-A: In the first part of the study the characterization of under-supplied patients as a target group is carried out by a secondary data analysis. In addition, patients and all stakehol
Sponsors
Universitätsklinikum HeidelbergKlinik für Allgemeine Innere Medizin und Psychosomatik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Persons, who belong to at least one of the following groups: patients with clinically significant psychological symptoms, general practitioners, medical specialists in a family practice, medical and psychological psychotherapists, health policymakers and written informed informed consent and must be minimum 18 years old
Exclusion criteria
Exclusion criteria: no given informed consent, inadequate language skills, and / or cognitive impairment which excludes the completion of the questionnaires or participation in the interviews or focus groups (Clinical impression, possibly objectified through 6-item-screener) or / and with patients: a) existence of severe mental health problems that need immediate other Treatment (e.g., acute suicidal ideation, acute psychosis), and b) those already in specialist treatment for depression or anxiety
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A) Current practice: current health care of patients with mental disorders in general practitioners' practice (especially with regard to under / over-care) B) Acceptability: need for low-threshold specialist psychotherapeutic care and willingness to implement (problem-consciousness and readiness for change) C) Appropriateness: potential to implement videoconsultation, compatibility as well as necessary adaptations and core elements of the proposed PROVIDE treatment model D) Feasibility: possible barriers and conductive factors for implementing videoconsultation | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes of the PROVIDE-C trial include differences of the absolute change in mean depressive and anxiety symptom severity on the PHQ-ADS at 12 months between both study arms. At 6 and 12 months after baseline assessment, we will also calculate the absolute change in mean depressive and anxiety symptom severity on the PHQ-9 and GAD-7, respectively along with differences in mean burden of specific somatic complaints (Somatic Symptom Disorder–B Criteria Scale, SSD-12), recovery (Recovery Assessment Scale, RAS-G), health-related quality of life (SF-12 questionnaire, and EQ-5D 5 L), quality and patient-centredness of chronic illness care (Patient Assessment of Chronic Illness Care–Short Form, PACIC–Short Form), adverse effects (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP), and health service use (Questionnaire for the Assessment of Medical and non-Medical Resource Utilisation in Mental Disorders, FIMPsy) between both study arms. The cost-effectiveness of the primary care embedded MHSVC model of care compared to usual care over the study period will comprise additional secondary outcomes. | — |
Countries
Germany
Contacts
Public ContactMarkus Haun
Universitätsklinikum Heidelberg
Outcome results
None listed